Milestones in ataxia
dc.contributor.author | Klockgether, Thomas | en_US |
dc.contributor.author | Paulson, Henry L. | en_US |
dc.date.accessioned | 2011-06-10T14:21:36Z | |
dc.date.available | 2012-06-15T14:07:14Z | en_US |
dc.date.issued | 2011-05 | en_US |
dc.identifier.citation | Klockgether, Thomas; Paulson, Henry (2011). "Milestones in ataxia." Movement Disorders 26(6): 1134-1141. <http://hdl.handle.net/2027.42/84413> | en_US |
dc.identifier.issn | 0885-3185 | en_US |
dc.identifier.issn | 1531-8257 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/84413 | |
dc.description.abstract | The past 25 years have seen enormous progress in the deciphering of the genetic and molecular basis of ataxias, resulting in improved understanding of their pathogenesis. The most significant milestones during this period were the cloning of the genes associated with the common spinocerebellar ataxias, ataxia telangiectasia, and Friedreich ataxia. To date, the causative mutations of more than 30 spinocerebellar ataxias and 20 recessive ataxias have been identified. In addition, there are numerous acquired ataxias with defined molecular causes, so that the entire number of distinct ataxia disorders exceeds 50 and possibly approaches 100. Despite this enormous heterogeneity, a few recurrent pathophysiological themes stand out. These include protein aggregation, failure of protein homeostasis, perturbations in ion channel function, defects in DNA repair, and mitochondrial dysfunction. The clinical phenotypes of the most common ataxia disorders have been firmly established, and their natural history is being studied in ongoing large observational trials. Effective therapies for ataxias are still lacking. However, novel drug targets are under investigation, and it is expected that there will be an increasing number of therapeutic trials in ataxia. © 2011 Movement Disorder Society | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Neurology | en_US |
dc.subject.other | Neuroscience | en_US |
dc.title | Milestones in ataxia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Neurology, University Hospital Bonn, Bonn, Germany ; German Center for Neurodegenerative Disorder (DZNE), Bonn, Germany ; Department of Neurology, University Hospital Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany | en_US |
dc.identifier.pmid | 21626557 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/84413/1/23559_ftp.pdf | |
dc.identifier.doi | 10.1002/mds.23559 | en_US |
dc.identifier.source | Movement Disorders | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.